CAR-T
4 stories
-
healthCAR-T Trial Access Disparities Persist for HIV Patients
HIV-positive individuals face longer travel times and fewer clinical trial options for CAR-T therapy in non-Hodgkin lymphoma, a new study reveals.
-
healthLymphocyte Growth Rate Key Predictor for CAR-T Therapy Success in Lymphoma
New research reveals lymphocyte expansion speed post-CAR-T therapy is a critical biomarker for predicting survival and toxicity in lymphoma patients.
-
healthCAR-T Therapy Demonstrates Significant Progress in Stiff Person Syndrome Study
Pivotal Phase II KYSA-8 study presented at AAN 2026 shows CAR-T therapy miv-cel offers substantial clinical improvements for Stiff Person Syndrome patients.
-
healthEli Lilly Acquires Kelonia Therapeutics for Up to $7 Billion in Cancer Therapy Push
Eli Lilly announces a major acquisition of Kelonia Therapeutics for up to $7 billion, bolstering its cell therapy pipeline with a novel in vivo cancer treatment.